CD14 and cancer: RuminococcaceaeUCG005 (OR: 1.067, 95% CI: 1.020–1.124, p = 0.018), BAFF-R on B cell (OR: 0.932, 95% CI: 0.826–0.987, p = 0.021), BAFF-R on CD20− CD38− (OR: 0.901, 95% CI: 0.816–0.994, p = 0.038), CD14− CD16− AC (OR: 1.073, 95% CI: 1.022–1.115, p = 0.017), CD24 on IgD+ CD38br (OR: 1.127, 95% CI: 1.051–1.209, p = 0.015), CD8 on CD39+ CD8br (OR: 0.900, 95% CI: 0.815–0.993, p = 0.045), CD14 on CD14+ CD16+ monocyte (OR: 1.064, 95% CI: 1.0023–1.117, p = 0.014), and CX3CR1 on monocyte (OR: 0.954, 95% CI: 0.848–0.999, p = 0.019) were significantly correlated with the risk of MT.